LifeNet Health Announces First Bio-Implant with New Preservation Technology

VIRGINIA BEACH, Va., Nov. 9 /PRNewswire/ -- LifeNet Health, a leading
allograft bio-implant company, announces the launch of Vertigraft Cervical
Bio-Implant (VG2C) with Preservon® Technology

Preservon® is a new, proprietary glycerol-based preservation solution that
allows allograft bio-implants to be stored in a fully hydrated state at
ambient temperature. This eliminates the need to freeze or freeze-dry
bio-implants, doing away with lengthy thawing and rehydration times in
operating rooms. VG2C with Preservon® represents the first machined composite
bio-implant allografts delivered to the operating room in a fully hydrated
state without the need for frozen storage.

VG2C allograft bio-implants in frozen form have been one of the most widely
utilized machined allografts for anterior cervical fusion surgery, with over
200,000 grafts distributed since 2002. This new ambient storage packaging
provides greater convenience for the hospital and OR staff and eliminates the
need for expensive freezer storage while retaining the proven performance that
surgeons have grown to trust for their patients.

Preservon® combined with LifeNet Health's patented Allowash XG process
delivers a sterile (SAL of 10(-6)) allograft bio-implant with the full
mechanical properties associated with frozen grafts in an ambient storage
package.

"This is a leading advancement in our field. Preservon® allograft
bio-implants will save valuable OR time and preserve product integrity. It
will benefit surgeons, hospitals and most importantly the patients whom we
serve. This is part of our mission in saving lives and restoring health,"
said Rony Thomas, LifeNet Health CEO and President.

Preservon® is one of several process technology platforms that LifeNet Health
has developed to enhance the utility and clinical effectiveness of human
allograft tissue. LifeNet Health is currently evaluating other applications
that can benefit from this break-through technology including skin, cartilage
and other cardiovascular tissues.

Since 1995, LifeNet Health has distributed more than two million bio-implants
with no incidence of disease transmission linked to tissue screened and
processed using LifeNet Health's proprietary Allowash XG® technology. All
allograft tissue undergoes a multi-step quality assurance review that exceeds
the standards set by both the FDA and American Association of Tissue Banks
(AATB).

About LifeNet Health
LifeNet Health, a non-profit global leader in regenerative medicine, is the
world's largest provider of bio-implants and organs for transplantation whose
mission is saving lives and restoring health by advancing the field of tissue
engineering.

For additional information about LifeNet Health, visit www.lifenethealth.org.

SOURCE LifeNet Health

Dena Reynolds of LifeNet Health, +1-800-847-7831,
dena_reynolds@lifenethealth.org